Landos Biopharma Stock Forecast, Price & News

+0.22 (+2.22 %)
(As of 04/12/2021 05:20 PM ET)
Today's Range
Now: $10.15
50-Day Range
MA: $12.52
52-Week Range
Now: $10.15
Volume117,193 shs
Average Volume297,024 shs
Market Capitalization$407.20 million
P/E RatioN/A
Dividend YieldN/A
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and inflammatory bowel diseases. The company also develops NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1, a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and PX-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and rheumatoid arthritis. The company was founded in 2017 and is headquartered in Blacksburg, Virginia.
Landos Biopharma logo

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolNASDAQ:LABP
Phone540 218 1767
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Market Cap$407.20 million
Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

1.81 out of 5 stars

Medical Sector

142nd out of 2,011 stocks

Biotechnology Industry

12th out of 143 stocks

Analyst Opinion: 3.4Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
+0.22 (+2.22 %)
(As of 04/12/2021 05:20 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LABP News and Ratings via Email

Sign-up to receive the latest news and ratings for LABP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Landos Biopharma (NASDAQ:LABP) Frequently Asked Questions

Is Landos Biopharma a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Landos Biopharma in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Landos Biopharma stock.
View analyst ratings for Landos Biopharma
or view top-rated stocks.

What stocks does MarketBeat like better than Landos Biopharma?

Wall Street analysts have given Landos Biopharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Landos Biopharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for LABP?

4 Wall Street analysts have issued twelve-month price objectives for Landos Biopharma's stock. Their forecasts range from $17.00 to $33.00. On average, they expect Landos Biopharma's stock price to reach $25.50 in the next twelve months. This suggests a possible upside of 151.2% from the stock's current price.
View analysts' price targets for Landos Biopharma
or view top-rated stocks among Wall Street analysts.

Who are Landos Biopharma's key executives?

Landos Biopharma's management team includes the following people:
  • Dr. Josep Bassaganya-Riera DVM, Ph.D., Chairman, Pres & CEO (Age 46, Pay $741.77k)
  • Ms. Jyoti Chauhan M.S., Exec. VP of Operations & Regulatory Affairs (Age 32, Pay $281.42k)
  • Dr. Raquel Hontecillas DVM, Ph.D., Chief Scientific Officer (Age 49, Pay $228.76k)
  • Ms. Jennifer Collette CPA, VP of Fin. & Controller

Who are some of Landos Biopharma's key competitors?

When did Landos Biopharma IPO?

(LABP) raised $101 million in an IPO on Thursday, February 4th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and SVB Leerink acted as the underwriters for the IPO and Raymond James was co-manager.

What is Landos Biopharma's stock symbol?

Landos Biopharma trades on the NASDAQ under the ticker symbol "LABP."

When does Landos Biopharma's lock-up period expire?

Landos Biopharma's lock-up period expires on Tuesday, August 3rd. Landos Biopharma had issued 6,250,000 shares in its initial public offering on February 4th. The total size of the offering was $100,000,000 based on an initial share price of $16.00. After the end of Landos Biopharma's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

How do I buy shares of Landos Biopharma?

Shares of LABP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Landos Biopharma's stock price today?

One share of LABP stock can currently be purchased for approximately $10.15.

How much money does Landos Biopharma make?

Landos Biopharma has a market capitalization of $407.20 million.

How many employees does Landos Biopharma have?

Landos Biopharma employs 33 workers across the globe.

What is Landos Biopharma's official website?

The official website for Landos Biopharma is

How can I contact Landos Biopharma?

The company can be reached via phone at 540 218 1767.

This page was last updated on 4/12/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.